Gubra A/S (GUBRA) - Total Liabilities
Based on the latest financial reports, Gubra A/S (GUBRA) has total liabilities worth Dkr1.69 Billion DKK (≈ $265.17 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Gubra A/S cash conversion from operations to assess how effectively this company generates cash.
Gubra A/S - Total Liabilities Trend (2019–2024)
This chart illustrates how Gubra A/S's total liabilities have evolved over time, based on quarterly financial data. Check Gubra A/S (GUBRA) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Gubra A/S Competitors by Total Liabilities
The table below lists competitors of Gubra A/S ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Luzerner Kantonalbank AG
LSE:0QNU
|
UK | £58.72 Billion |
|
Guizhou Guihang Automotive Components Co Ltd
SHG:600523
|
China | CN¥865.89 Million |
|
Zhejiang Huakang Pharmaceutical Co Ltd
SHG:605077
|
China | CN¥4.32 Billion |
|
PPHE Hotel Group Ltd
F:32P
|
Germany | €1.40 Billion |
|
Guangdong Xinhui Meida Nylon Co Ltd
SHE:000782
|
China | CN¥1.32 Billion |
|
Jiangxi Naipu Mining Machinery
SHE:300818
|
China | CN¥1.27 Billion |
|
Dongkuk Steel Mill Co Ltd
KO:001230
|
Korea | ₩739.61 Billion |
|
Zhejiang Zanyu Technology Co Ltd
SHE:002637
|
China | CN¥4.60 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Gubra A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Gubra A/S stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gubra A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gubra A/S (2019–2024)
The table below shows the annual total liabilities of Gubra A/S from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Dkr161.91 Million ≈ $25.33 Million |
+11.19% |
| 2023-12-31 | Dkr145.62 Million ≈ $22.78 Million |
-5.87% |
| 2022-12-31 | Dkr154.69 Million ≈ $24.20 Million |
+2.68% |
| 2021-12-31 | Dkr150.66 Million ≈ $23.57 Million |
+30.82% |
| 2020-12-31 | Dkr115.17 Million ≈ $18.02 Million |
+8.28% |
| 2019-12-31 | Dkr106.36 Million ≈ $16.64 Million |
-- |
About Gubra A/S
Gubra A/S, a biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally. The company operates through three segments: Pre-Clinical Contract Research (CRO), Discovery & Partnerships, and Gubra Green. It offers pre-clinical contract research and development services within metab… Read more